Mediwound (MDWD) has released an update.
MediWound Ltd. has achieved a significant milestone with the FDA’s approval of NexoBrid for treating severe thermal burns in pediatric patients, making it available for all ages in the U.S. The approval is backed by global Phase III clinical trials and positions NexoBrid as a non-surgical alternative for burn care. This enzymatic therapy aligns with the company’s mission to revolutionize burn treatment, already approved across over 40 countries, including the EU and Japan.
For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.
